RIG-1/DDX58: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of RIG-1/DDX58. The page also collects GeneMedi's different modalities and formats products for RIG-1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the RIG-1 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases which are implicated in a number of cellular processes involving RNA binding and alteration of RNA secondary structure. This gene encodes a protein containing RNA helicase-DEAD box protein motifs and a caspase recruitment domain (CARD). It is involved in viral double-stranded (ds) RNA recognition and the regulation of the antiviral innate immune response. Mutations in this gene are associated with Singleton-Merten syndrome 2. [provided by RefSeq, Aug 2020]

Target IDGM-T29339
Target NameRIG-1
Gene ID23586,230073,297989,704638,100855560,101095926,504760,100067920
Gene Symbol and Synonyms6430573D20Rik,C330021E21,DDX58,RIG-I,RIG1,RIGI,RLR-1,SGMRT2
Uniprot AccessionO95786
Uniprot Entry NameDDX58_HUMAN
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, Immuno-oncology Target
DiseaseN/A
Gene EnsemblENSG00000107201
Target ClassificationCheckpoint-Immuno Oncology


Pre-made anti-RIG-1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-RIG-1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-RIG-1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-RIG-1/DDX58 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional Antibody, Therapeutics Target antibodyDetail



Multi-species DDX58/ RIG-1/ RIG-I VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RIG-1/DDX58 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
RIG-1/DDX58 VLP (virus-like particle)Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellProducts Developing